Computational insights into inhibitory mechanism of azole compounds against human aromatase

Human aromatase, also known as cytochrome P450 19A1, specifically catalyzes the conversion of androgens to estrogens, and therefore represents an important drug target for the treatment of breast cancer. Recently, azole compounds previously used as agricultural fungicides and antimycotic drugs were reported to exhibit potent inhibitory activity against aromatase. However, the molecular mechanism of these azole compounds against aromatase remains unclear. In this study, a combination of molecular docking and several types of molecular dynamics (MD) simulations including conventional MD, random acceleration MD and steered MD, was employed to investigate the interactions of aromatase with letrozole and imazalil, two azole compounds with distinct inhibitory activities against aromatase. The binding modes of these two inhibitors were obtained by molecular docking and refined by MD simulation. The binding free energies were calculated based on the MD snapshots by using the MM-GBSA method and were found to be in agreement with the relative potency of the experimental binding affinities. Our results further demonstrated that these inhibitors had different favorable unbinding pathways in aromatase, and the unbinding manners differed in their favorable dissociation routes. Several residues lining the pathways were found important for the inhibitor egress. These findings would be helpful not only for understanding the inhibitory mechanism of azole compounds against aromatase, but also for designing new aromatase inhibitors.

[1]  Ruth Nussinov,et al.  Theoretical Characterization of Substrate Access/Exit Channels in the Human Cytochrome P450 3A4 Enzyme: Involvement of Phenylalanine Residues in the Gating Mechanism , 2009, The journal of physical chemistry. B.

[2]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[3]  R. Wade,et al.  How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms. , 2000, Journal of molecular biology.

[4]  Weihua Li,et al.  Exploring coumarin egress channels in human cytochrome p450 2a6 by random acceleration and steered molecular dynamics simulations , 2011, Proteins.

[5]  Alessandra Magistrato,et al.  Computational Approaches Elucidate the Allosteric Mechanism of Human Aromatase Inhibition: A Novel Possible Route to Small-Molecule Regulation of CYP450s Activities? , 2014, J. Chem. Inf. Model..

[6]  Jessica Lo,et al.  Novel aromatase inhibitors by structure-guided design. , 2012, Journal of medicinal chemistry.

[7]  Giulio Rastelli,et al.  Structure-based design of potent aromatase inhibitors by high-throughput docking. , 2011, Journal of medicinal chemistry.

[8]  R. Santen,et al.  History of aromatase: saga of an important biological mediator and therapeutic target. , 2009, Endocrine reviews.

[9]  Helmut Grubmüller,et al.  Ligand-release pathways in the pheromone-binding protein of Bombyx mori. , 2006, Structure.

[10]  L. Waskell,et al.  Theoretical study of the ligand–CYP2B4 complexes: Effect of structure on binding free energies and heme spin state , 2004, Proteins.

[11]  Andrea Cavalli,et al.  Steered Molecular Dynamics Simulations for Studying Protein-Ligand Interaction in Cyclin-Dependent Kinase 5 , 2014, J. Chem. Inf. Model..

[12]  Silvia Gobbi,et al.  Imidazolylmethylbenzophenones as highly potent aromatase inhibitors. , 2007, Journal of medicinal chemistry.

[13]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[14]  M. Waterman,et al.  CYP51—the omnipotent P450 , 2004, Molecular and Cellular Endocrinology.

[15]  D. Ghosh,et al.  Evidence for an Elevated Aspartate pKa in the Active Site of Human Aromatase* , 2014, The Journal of Biological Chemistry.

[16]  R. Brueggemeier,et al.  The final catalytic step of cytochrome p450 aromatase: a density functional theory study. , 2005, Journal of the American Chemical Society.

[17]  A. Capelli,et al.  Unbinding pathways from the glucocorticoid receptor shed light on the reduced sensitivity of glucocorticoid ligands to a naturally occurring, clinically relevant mutant receptor. , 2013, Journal of medicinal chemistry.

[18]  R. Coombes,et al.  Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. , 1992, Cancer research.

[19]  Leandro Martínez,et al.  Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands. , 2006, Journal of medicinal chemistry.

[20]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[21]  K. Korzekwa,et al.  Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. , 2001, European journal of biochemistry.

[22]  Rebecca C Wade,et al.  Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling? , 2005, EMBO reports.

[23]  Y. Duan,et al.  Ligand entry and exit pathways in the beta2-adrenergic receptor. , 2009, Journal of molecular biology.

[24]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[25]  W. Pangborn,et al.  Structural basis for androgen specificity and oestrogen synthesis in human aromatase , 2009, Nature.

[26]  Marwen Naïm,et al.  Molecular dynamics-solvated interaction energy studies of protein-protein interactions: the MP1-p14 scaffolding complex. , 2008, Journal of molecular biology.

[27]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[28]  Dusanka Janezic,et al.  Harmonic analysis of large systems. I. Methodology , 1995, J. Comput. Chem..

[29]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[30]  K. Schulten,et al.  Steered molecular dynamics and mechanical functions of proteins. , 2001, Current opinion in structural biology.

[31]  Martin van den Berg,et al.  A comparison of human H295R and rat R2C cell lines as in vitro screening tools for effects on aromatase. , 2004, Toxicology letters.

[32]  E. Simpson,et al.  Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis. , 1993, Molecular endocrinology.

[33]  A. Bhatnagar,et al.  Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. , 1996, Acta oncologica.

[34]  Quentin Kaas,et al.  Delineation of the unbinding pathway of α-conotoxin ImI from the α7 nicotinic acetylcholine receptor. , 2012, The journal of physical chemistry. B.

[35]  Jan H. Jensen,et al.  Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. , 2011, Journal of chemical theory and computation.

[36]  P. Cole,et al.  Mechanism and inhibition of cytochrome P-450 aromatase. , 1990, Journal of medicinal chemistry.

[37]  Qingchuan Zheng,et al.  Molecular basis of the recognition of arachidonic acid by cytochrome P450 2E1 along major access tunnel , 2015, Biopolymers.

[38]  Weiliang Zhu,et al.  Possible Pathway(s) of Metyrapone Egress from the Active Site of Cytochrome P450 3A4: A Molecular Dynamics Simulation , 2007, Drug Metabolism and Disposition.

[39]  D. Ghosh,et al.  Mechanism of inhibition of estrogen biosynthesis by azole fungicides. , 2014, Endocrinology.

[40]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[41]  F. Guengerich,et al.  Mechanism of the Third Oxidative Step in the Conversion of Androgens to Estrogens by Cytochrome P450 19A1 Steroid Aromatase , 2014, Journal of the American Chemical Society.

[42]  Rebecca C Wade,et al.  Multiple, ligand-dependent routes from the active site of cytochrome P450 2C9. , 2012, Current drug metabolism.

[43]  Lennart Nilsson,et al.  Ligand unbinding from the estrogen receptor: A computational study of pathways and ligand specificity , 2009, Proteins.

[44]  Feixiong Cheng,et al.  Investigation of Indazole Unbinding Pathways in CYP2E1 by Molecular Dynamics Simulations , 2012, PloS one.

[45]  Rebecca C Wade,et al.  The ins and outs of cytochrome P450s. , 2007, Biochimica et biophysica acta.

[46]  Wolfgang Völkel,et al.  Comparative Assessment of the Inhibition of Recombinant Human CYP19 (Aromatase) by Azoles Used in Agriculture and as Drugs for Humans , 2004, Endocrine research.

[47]  P. Kollman,et al.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.

[48]  Alessandra Magistrato,et al.  Influence of the Membrane Lipophilic Environment on the Structure and on the Substrate Access/Egress Routes of the Human Aromatase Enzyme. A Computational Study , 2012, J. Chem. Inf. Model..

[49]  K. Sharp,et al.  Calculating the electrostatic potential of molecules in solution: Method and error assessment , 1988 .

[50]  Angelo Carotti,et al.  Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase. , 2011, Journal of medicinal chemistry.

[51]  S. Yee,et al.  Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation. , 2006, Journal of medicinal chemistry.

[52]  Rebecca C Wade,et al.  Conformational diversity and ligand tunnels of mammalian cytochrome P450s , 2013, Biotechnology and applied biochemistry.

[53]  G. Gilardi,et al.  Human aromatase: Perspectives in biochemistry and biotechnology , 2013, Biotechnology and applied biochemistry.

[54]  Sundarapandian Thangapandian,et al.  Probing possible egress channels for multiple ligands in human CYP3A4: A molecular modeling study , 2010, Journal of molecular modeling.

[55]  Weihua Li,et al.  Reduced Catalytic Activity of P450 2A6 Mutants with Coumarin: A Computational Investigation. , 2009, Journal of chemical theory and computation.

[56]  Jing Fu,et al.  Unbinding Pathways of GW4064 from Human Farnesoid X Receptor As Revealed by Molecular Dynamics Simulations , 2012, J. Chem. Inf. Model..

[57]  M. Dowsett,et al.  ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[58]  Chartchalerm Isarankura-Na-Ayudhya,et al.  Molecular Docking of Aromatase Inhibitors , 2011, Molecules.

[59]  Rommie E. Amaro,et al.  Molecular Simulations of Aromatase Reveal New Insights Into the Mechanism of Ligand Binding , 2013, J. Chem. Inf. Model..

[60]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[61]  P. Tavan,et al.  Ligand Binding: Molecular Mechanics Calculation of the Streptavidin-Biotin Rupture Force , 1996, Science.

[62]  D. Ghosh,et al.  Motion and Flexibility in Human Cytochrome P450 Aromatase , 2012, PloS one.

[63]  M. Peräkylä Ligand unbinding pathways from the vitamin D receptor studied by molecular dynamics simulations , 2009, European Biophysics Journal.

[64]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[65]  B. Potter,et al.  Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates , 2011, ChemMedChem.

[66]  R. Galeazzi,et al.  Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study , 2012, Journal of Molecular Modeling.